Boothbay Fund Management’s Spyre Therapeutics SYRE Stock Holding History

Boothbay Fund Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$573K	Sell	6,453 -186,578	-97%	-$13.6M	0.01%	1407
2026 Q1	$9.74M	Buy	+193,031	New	+$7.28M	0.13%	139
2025 Q1	–	Sell	-85,618	Closed	-$1.99M	–	1776
2024 Q4	$1.99M	Sell	85,618 -6,157	-7%	-$181K	0.05%	449
2024 Q3	$2.7M	Buy	+91,775	New	+$2.56M	0.06%	433
2020 Q4	–	Sell	-423	Closed	-$75K	–	1407
2020 Q3	$75K	Buy	+423	New	+$78.3K	﹤0.01%	990

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Boothbay Fund Management's SYRE Position: Q2 2026 in Review

Boothbay Fund Management reduced its Spyre Therapeutics (SYRE) stake by 97% in Q2 2026, selling an estimated $13.6M and leaving 6,453 shares worth $573K. The position accounts for 0.01% of the portfolio, ranked #1407.

Boothbay Fund Management first reported a position in SYRE in Q3 2020 and has held it in 5 quarters since. The position peaked at $9.74M in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Boothbay Fund Management held 6,453 shares of Spyre Therapeutics worth $573K as of Q2 2026.
Boothbay Fund Management sold 186,578 Spyre Therapeutics shares in Q2 2026, an estimated $13.6M.
Spyre Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1407 holding.
Boothbay Fund Management first reported a position in Spyre Therapeutics in Q3 2020 and has held it in 5 quarters since.
Boothbay Fund Management's Spyre Therapeutics position peaked at $9.74M in Q1 2026.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.